Johnson & Johnson recently said that a real-world study showed its single-shot COVID-19 vaccine protects against breakthrough infections and hospitalsations for up to six months.
The study, sponsored by the vaccine developer, was conducted between 1st January and 7th September last year, before the Omicron variant was discovered.
It is also yet to be peer-reviewed.
J&J said protection against infection from its single-dose vaccine starts to wane only from the fourth month compared to the second month in the case of two-dose vaccines from rivals Pfizer Inc and BioNTech’s as well as Moderna.
No waning of protection was found for ICU admissions for all the three vaccines, J&J said.
The company said the study was carried out by collecting claims and laboratory data covering 168 million people.